Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
Community Resources
Our Expert Network

CME & Education About Us

Loading...

CME & Education About Us

Loading profile...

Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
Community Resources
Our Expert Network

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved

Injecting on Bone: A Practical Approach to Filler Safety

Home
Videos
Discourses In Dermatology
Approach To Filler Safety

#top-leaderboard-ads, .stickyads { position: static !important; }

Injecting on Bone: A Practical Approach to Filler Safety

Featuring:

GGGary Goldenberg, MDCo-Director

Updated:Mar 26, 2026

Aesthetics Aesthetics

About this video

A simple adjustment in technique that can make a meaningful difference in filler safety.

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

What Changes When We Treat Psoriasis as Systemic Disease?

What Changes When We Treat Psoriasis as Systemic Disease?

Who to Look for and When to Act

Who to Look for and When to Act

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

Injecting on Bone: A Practical Approach to Filler Safety

Injecting on Bone: A Practical Approach to Filler Safety

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

Bullous Pemphigoid: The Evolving Treatment Landscape

Bullous Pemphigoid: The Evolving Treatment Landscape

Confirming BP Diagnosis and Choosing Treatment

Confirming BP Diagnosis and Choosing Treatment

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

What Four Years Can Tell Us About Treating Moderate to Severe HS

What Four Years Can Tell Us About Treating Moderate to Severe HS

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

Leading With Intention in Aesthetic Assessment

Leading With Intention in Aesthetic Assessment

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

Topical Truths: Managing AD in the Real World

Topical Truths: Managing AD in the Real World

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

Four Years of Data: Durability and Distinction with TYK2 Inhibition

Four Years of Data: Durability and Distinction with TYK2 Inhibition

What an Oral Option Means for Psoriasis Care

What an Oral Option Means for Psoriasis Care

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

VTAMA: A New Standard in Psoriasis Management

VTAMA: A New Standard in Psoriasis Management

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

Psoriasis mechanism of disease: Pathogenesis

Psoriasis mechanism of disease: Pathogenesis

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors